Advertisement

Topics

AZ’ Fasenra gets US nod for eosinophilic asthma

05:17 EST 15 Nov 2017 | PharmaTimes

AstraZeneca’s biologic Fasenra has picked up its first global approval in the US as a treatment for severe, eosinophilic asthma, a difficult to treat form of the condition.

Original Article: AZ’ Fasenra gets US nod for eosinophilic asthma

NEXT ARTICLE

More From BioPortfolio on "AZ’ Fasenra gets US nod for eosinophilic asthma"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Pulmonary
Pulmonary relating to or associated with the lungs eg Asthma, chronic bronchitis, emphysema, COPD, Cystic Fibrosis, Influenza,  Lung Cancer, Pneumonia, Pulmonary Arterial Hypertension, Sleep Disorders etc Follow and track Lung Cancer News ...